ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CLNN vs ABBV // FREE CASH FLOW YIELD

Clene Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CLNN 1 — ABBV 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLNN VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CLNN ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 78.50% 70.20% +8.30 CLNN /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 29.00% -64.00 ABBV /roic <GO>
EV/EBITDA & P/E Valuation — 33.3x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — 3.47% — TIE /fcf-yield <GO>
Operating Margin -60.00% 24.60% -84.60 ABBV /operating-margins <GO>
Net Profit Margin -60.00% 6.90% -66.90 ABBV /net-margins <GO>
Revenue Growth (YoY) -41.50% 8.60% -50.10 ABBV /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 ABBV /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.4 65.1 -15.69 ABBV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 113.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $55.4M $513.86B -$513.80B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CLNN REV ABBV REV CLNN GROSS % ABBV GROSS % CLNN FCF ABBV FCF
FY 2025 $200.0K $61.16B 78.5% 70.2% -$18.6M $17.82B
FY 2024 $342.0K $56.33B 79.5% 70.0% -$21.3M $17.83B
FY 2023 $654.0K $54.32B — — -$30.2M $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLNN // BETA —
ABBV // BETA 1.15